Last reviewed · How we verify
SGAs
At a glance
| Generic name | SGAs |
|---|---|
| Also known as | second-generation antipsychotics |
| Sponsor | Calo Psychiatric Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of SaCo VLMA for General Anesthesia for Laparoscopic Procedures (NA)
- Predicting 28-Day Survival in OHCA Patients
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT) (PHASE3)
- Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs (PHASE4)
- Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
- I-gel vs AuraGain for Bronchoscopic Intubation Through SGA (NA)
- The Effect of Hawthorn on Lipoprotein Cholesterol Ratio in Schizophrenics With Antipsychotics (NA)
- Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SGAs CI brief — competitive landscape report
- SGAs updates RSS · CI watch RSS
- Calo Psychiatric Center portfolio CI